Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9719599 | 0.93 | TSHR (0.46) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL522175 | 0.88 | TSHR (0.61) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL27971417 | 0.86 | TSHR (0.45) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL10626508 | 0.86 | TSHR (0.41) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL1719721 | 0.85 | TSHR (0.59) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL7198377 | 0.83 | TSHR (0.57) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL27556372 | 0.82 | KDM4E (0.41) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL522412 | 0.80 | TSHR (0.53) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL31217521 | 0.80 | TSHR (0.50) | TSHRMAPK1MAPTCA12CA1 | |
| SCHEMBL19478152 | 0.79 | TSHR (0.42) | TSHRMAPK1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| EP-3935060-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | Astrazeneca AB (SE) | 2022-01-12 | — | — | EP | disclosed |
| CN-113508118-A | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-109053723-B | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2021-09-03 | — | — | CN | disclosed |
| US-11084002-B2 | Universal scalable and cost-effective surface modifications | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| WO-2014130844-A1 | UNIVERSAL SCALABLE AND COST-EFFECTIVE SURFACE MODIFICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-5280044-A | Fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0381330-B1 | Fungicides | ZENECA LTD (GB) | 1993-12-29 | — | — | EP | disclosed |
| US-4999381-A | Fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-03-12 | — | — | US | disclosed |
| EP-0381330-A1 | Fungicides | ZENECA LIMITED (GB) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | TSHR 2944/4885MAPK1 2093/4885MAPT 3149/4885 |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | TSHR 2913/4885MAPK1 3576/4885MAPT 3410/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | TSHR 2944/4885MAPK1 2093/4885MAPT 3149/4885 |
| US-11084002-B2 | Universal scalable and cost-effective surface modifications | EPCAM, CD59, SIGLEC9 | TSHR 2555/4885MAPK1 4633/4885MAPT 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.